Finally, FDA Approval!

Each week, we like to take a moment to boil down the biggest news from the most influential companies in the pharmaceuticals industry and tell our viewers what that news means for you. We call that segment our Big Pharma Roundup.

In this week's installment, Johnson & Johnson (NYSE: JNJ) saw its Fibrin Pad receive FDA approval recently. The pad stops bleeding by promoting blood clots and gives the company further exposure to the $3 billion wound-closure market. In this video, Motley Fool health-care analyst Brenton Flynn tells investors how the approval is going to affect them.

In the world of health care, companies simply don't come any bigger than Johnson & Johnson. Many own the stock, but few understand its story. Offering everything from baby powder to biologics, critics think the company has spread itself too thin, becoming nothing more than a bloated corporate whale. Is this true, or is J&J a well-diversified giant that's perfect for your portfolio? Make sure you understand the full story behind the stock, along with its key opportunities and risks, by checking out our brand-new premium report on Johnson & Johnson. To claim your copy, simply click here now for instant access.


Read/Post Comments (0) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

DocumentId: 2155990, ~/Articles/ArticleHandler.aspx, 7/24/2014 12:21:55 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement